Abstract
Congressional and presidential records reveal a consistent pattern of political intercession with the regulatory authority of the Food and Drug Administration (FDA) over the approval and labeling of mifepristone (RU-486). This pattern is unlikely to abate any time soon. It is against this backdrop that we examine herein the ongoing legislative and legal disputes over mifepristone at a point in time which is just beyond the 20th anniversary of its approval by the FDA “for the medical termination of intrauterine pregnancy.”
All Keywords
【저자키워드】 Pregnancy, abortion, progesterone, mifepristone, 【초록키워드】 drug, FDA, food, approval, labeling, regulatory authority, unlikely, RU-486, 【제목키워드】 history,
【저자키워드】 Pregnancy, abortion, progesterone, mifepristone, 【초록키워드】 drug, FDA, food, approval, labeling, regulatory authority, unlikely, RU-486, 【제목키워드】 history,